JP2014500009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500009A5 JP2014500009A5 JP2013537771A JP2013537771A JP2014500009A5 JP 2014500009 A5 JP2014500009 A5 JP 2014500009A5 JP 2013537771 A JP2013537771 A JP 2013537771A JP 2013537771 A JP2013537771 A JP 2013537771A JP 2014500009 A5 JP2014500009 A5 JP 2014500009A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 76
- 239000000427 antigen Substances 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 239000012634 fragment Substances 0.000 claims 37
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108010065637 Interleukin-23 Proteins 0.000 claims 3
- 102000013264 Interleukin-23 Human genes 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 2
- 101710195550 Interleukin-23 receptor Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41015810P | 2010-11-04 | 2010-11-04 | |
| US61/410,158 | 2010-11-04 | ||
| US41195310P | 2010-11-10 | 2010-11-10 | |
| US61/411,953 | 2010-11-10 | ||
| US41259410P | 2010-11-11 | 2010-11-11 | |
| US61/412,594 | 2010-11-11 | ||
| US201161448785P | 2011-03-03 | 2011-03-03 | |
| US61/448,785 | 2011-03-03 | ||
| PCT/US2011/058869 WO2012061448A1 (en) | 2010-11-04 | 2011-11-02 | Anti-il-23 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017003955A Division JP6445596B2 (ja) | 2010-11-04 | 2017-01-13 | 抗ｉｌ−２３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500009A JP2014500009A (ja) | 2014-01-09 |
| JP2014500009A5 true JP2014500009A5 (enExample) | 2014-12-25 |
| JP6126532B2 JP6126532B2 (ja) | 2017-05-10 |
Family
ID=44936573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537771A Active JP6126532B2 (ja) | 2010-11-04 | 2011-11-02 | 抗ｉｌ−２３抗体 |
| JP2017003955A Active JP6445596B2 (ja) | 2010-11-04 | 2017-01-13 | 抗ｉｌ−２３抗体 |
| JP2018223469A Active JP6758361B2 (ja) | 2010-11-04 | 2018-11-29 | 抗ｉｌ−２３抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017003955A Active JP6445596B2 (ja) | 2010-11-04 | 2017-01-13 | 抗ｉｌ−２３抗体 |
| JP2018223469A Active JP6758361B2 (ja) | 2010-11-04 | 2018-11-29 | 抗ｉｌ−２３抗体 |
Country Status (39)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| KR102049223B1 (ko) | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항－ｉｌ－２３ 항체 |
| CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| JOP20140049B1 (ar) * | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
| US20160031983A1 (en) | 2013-03-15 | 2016-02-04 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| EP3689369A1 (en) | 2013-03-15 | 2020-08-05 | Amgen, Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| EP3172339A1 (en) * | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| CA2959629C (en) | 2014-09-03 | 2023-10-31 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| KR20170120616A (ko) * | 2015-02-04 | 2017-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환의 치료 방법 |
| MX2017013156A (es) | 2015-04-14 | 2018-02-21 | Boehringer Ingelheim Int | Metodos para tratar enfermedades. |
| PE20180774A1 (es) * | 2015-07-23 | 2018-05-07 | Boehringer Ingelheim Int | Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos |
| MX2018003376A (es) * | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
| TWI811716B (zh) | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
| PT3370768T (pt) * | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| WO2017112536A1 (en) | 2015-12-22 | 2017-06-29 | Amgen Inc. | Ccl20 as a predictor of clinical response to il23-antagonists |
| AU2017250583A1 (en) | 2016-04-15 | 2018-08-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| WO2018071504A2 (en) | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| BR112020015909A2 (pt) * | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
| TWI744617B (zh) | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| JP2021532176A (ja) | 2018-07-13 | 2021-11-25 | アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニーAstrazeneca Collaboration Ventures, Llc | ブラジクマブによる潰瘍性大腸炎の処置 |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | 北京贝来生物科技有限公司 | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 |
| MX2021012652A (es) * | 2019-04-15 | 2022-01-24 | Sun Pharmaceutical Ind Ltd | Metodos para el tratamiento de sujetos con artritis psoriasica. |
| TW202535466A (zh) * | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| CA3164996A1 (en) * | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | 江苏荃信生物医药有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 |
| AR123477A1 (es) | 2020-09-10 | 2022-12-07 | Lilly Co Eli | Formulaciones de anticuerpos terapéuticos |
| KR20230086765A (ko) | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| WO2022251623A1 (en) | 2021-05-28 | 2022-12-01 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis |
| KR102761841B1 (ko) | 2021-07-09 | 2025-02-05 | 연세대학교 산학협력단 | Il-23에 의해 매개되는 질환의 중증도 예측용 조성물 |
| WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| US20240400670A1 (en) * | 2021-09-30 | 2024-12-05 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-il23 antibody fusion protein and uses thereof |
| WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
| JP2025535439A (ja) | 2022-10-21 | 2025-10-24 | チョン クン ダン ファーマシューティカル コーポレーション | 安定した抗体組成物 |
| KR20250152080A (ko) | 2023-02-22 | 2025-10-22 | 일라이 릴리 앤드 캄파니 | 궤양성 결장염에서의 유전자의 조절 및 그의 용도 |
| JP2026522632A (ja) * | 2023-06-22 | 2026-07-08 | パラゴン セラピューティクス、インコーポレイテッド | Ｉｌ－２３抗体組成物および使用法 |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| WO2025117506A1 (en) | 2023-11-29 | 2025-06-05 | Gilead Sciences, Inc. | Therapies for the treatment of inflammatory bowel disease |
| AU2025218720A1 (en) | 2024-02-06 | 2026-05-21 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025171006A1 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
| CN117875575B (zh) * | 2024-03-12 | 2024-05-28 | 中国电子科技集团公司第二十九研究所 | 一种基于混合仿生算法的干扰资源分配方法 |
| WO2026058045A1 (en) | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
| WO2026060205A1 (en) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| ZA986596B (en) | 1997-07-25 | 1999-02-08 | Schering Corp | Mammalian cytokine related reagents |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| AU2661199A (en) | 1998-02-06 | 1999-08-23 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| ATE474849T1 (de) | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
| DE60038304T3 (de) | 1999-09-09 | 2017-04-06 | Merck Sharp & Dohme Corp. | Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen |
| US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| US6756481B2 (en) | 2000-05-10 | 2004-06-29 | Schering Corporation | IL-23 receptor binding compositions |
| JPWO2003034818A1 (ja) | 2001-10-24 | 2005-02-10 | 中外製薬株式会社 | Ｓｇｒｆ遺伝子改変非ヒト動物 |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| NZ539271A (en) | 2002-10-30 | 2008-12-24 | Genentech Inc | Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23) |
| AU2003303384A1 (en) | 2002-12-23 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| ATE440864T1 (de) | 2003-03-10 | 2009-09-15 | Schering Corp | Verwendung von il-23-antagonisten; verwandte reagenzien |
| US7413894B2 (en) | 2003-07-01 | 2008-08-19 | University Of Virginia Patent Foundation | TAG-1 and TAG-2 proteins and uses thereof |
| AU2004287879C1 (en) | 2003-11-04 | 2011-05-26 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-CD40 monoclonal antibodies and methods for their use |
| PT1684805E (pt) | 2003-11-04 | 2010-10-26 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| CN1942201B (zh) | 2004-02-17 | 2012-06-20 | 先灵公司 | 调节il-23活性的方法；相关试剂 |
| AU2005241020B2 (en) | 2004-05-03 | 2008-07-10 | Merck Sharp & Dohme Corp. | Use of IL-17 expression to predict skin inflammation; methods of treatment |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| EP1799700A4 (en) * | 2004-09-27 | 2009-02-11 | Centocor Inc | SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1853707A2 (en) | 2004-12-20 | 2007-11-14 | Schering Corporation | Uses of il-23 antagonists in the treatment of diabetes mellitus |
| CA2613818C (en) | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| AU2006265898A1 (en) | 2005-06-30 | 2007-01-11 | Archemix Corp. | Polynucleotides and polypeptides of the IL-12 family of cytokines |
| SI1937721T1 (sl) * | 2005-08-25 | 2010-11-30 | Lilly Co Eli | Anti il protitelesa |
| CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
| ME02705B (me) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| DE602006009834D1 (de) | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| CN101389769A (zh) | 2005-12-28 | 2009-03-18 | 森托科尔公司 | 用于评价和治疗银屑病及相关疾病的标记与方法 |
| SI3219328T1 (sl) | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| CN101472611A (zh) | 2006-06-19 | 2009-07-01 | 惠氏公司 | 调节il-22和il-17的方法 |
| JP5419709B2 (ja) | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗ｉｌ−１３抗体製剤およびその使用 |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| AU2008216090A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein formulations containing sorbitol |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| CN103396489A (zh) * | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| MX2009009167A (es) | 2007-02-28 | 2009-09-04 | Schering Corp | Terapia de combinacion para el tratamiento de trastornos inmunes. |
| DK2197903T3 (en) | 2007-09-04 | 2015-01-05 | Us Gov Health & Human Serv | Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009053493A1 (en) | 2007-10-26 | 2009-04-30 | Galderma Research & Development | Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof |
| CA2607771A1 (en) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| MX2011001409A (es) | 2008-08-14 | 2011-03-29 | Cephalon Australia Pty Ltd | Anticuerpos anti-il-12/il-23. |
| WO2010027766A1 (en) | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| WO2010115786A1 (en) | 2009-04-01 | 2010-10-14 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| EP2414546A4 (en) | 2009-04-02 | 2013-03-13 | Univ Johns Hopkins | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASE AND COLON CARCINOMA |
| US20120269765A1 (en) | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| EP2504032A4 (en) | 2009-11-24 | 2013-06-19 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS |
| WO2011069000A2 (en) | 2009-12-02 | 2011-06-09 | Spartek Medical, Inc. | Low profile spinal prosthesis incorporating a bone anchor having a deflectable post and a compound spinal rod |
| GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
| PE20130041A1 (es) | 2010-02-18 | 2013-01-28 | Bristol Myers Squibb Co | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| SG184355A1 (en) | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
| JP2013531499A (ja) | 2010-06-15 | 2013-08-08 | セルジーン コーポレイション | 乾癬の治療のためのバイオマーカー |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| JP5972871B2 (ja) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｉｌ−２３ヘテロ二量体特異的抗体 |
| CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
| KR102049223B1 (ko) | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항－ｉｌ－２３ 항체 |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
| WO2012104402A1 (en) | 2011-02-04 | 2012-08-09 | Ab Science | Treatment of severe persitent asthma with masitinib |
| CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
| US20160031983A1 (en) | 2013-03-15 | 2016-02-04 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| EP3689369A1 (en) | 2013-03-15 | 2020-08-05 | Amgen, Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| CA2959629C (en) | 2014-09-03 | 2023-10-31 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| KR20170120616A (ko) | 2015-02-04 | 2017-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환의 치료 방법 |
| PE20180774A1 (es) | 2015-07-23 | 2018-05-07 | Boehringer Ingelheim Int | Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos |
| TWI811716B (zh) | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
-
2011
- 2011-11-02 KR KR1020187036509A patent/KR102049223B1/ko active Active
- 2011-11-02 PH PH1/2013/500810A patent/PH12013500810B1/en unknown
- 2011-11-02 CA CA3017116A patent/CA3017116A1/en not_active Abandoned
- 2011-11-02 MX MX2019000046A patent/MX2019000046A/es unknown
- 2011-11-02 EP EP16178404.6A patent/EP3115375A1/en not_active Withdrawn
- 2011-11-02 SG SG10201604605VA patent/SG10201604605VA/en unknown
- 2011-11-02 EA EA201890548A patent/EA201890548A1/ru unknown
- 2011-11-02 MX MX2013005015A patent/MX343858B/es active IP Right Grant
- 2011-11-02 AP AP2013006820A patent/AP3953A/en active
- 2011-11-02 PE PE2013000951A patent/PE20141162A1/es active IP Right Grant
- 2011-11-02 LT LTEP11781949.0T patent/LT2635601T/lt unknown
- 2011-11-02 JP JP2013537771A patent/JP6126532B2/ja active Active
- 2011-11-02 MX MX2016015419A patent/MX362039B/es unknown
- 2011-11-02 CN CN201180064083.5A patent/CN103282382B/zh active Active
- 2011-11-02 SG SG2013031745A patent/SG190006A1/en unknown
- 2011-11-02 DK DK11781949.0T patent/DK2635601T3/en active
- 2011-11-02 EA EA201300530A patent/EA030436B1/ru active Protection Beyond IP Right Term
- 2011-11-02 BR BR112013011065-1A patent/BR112013011065B1/pt active IP Right Grant
- 2011-11-02 NZ NZ610592A patent/NZ610592A/en unknown
- 2011-11-02 AU AU2011323426A patent/AU2011323426B2/en active Active
- 2011-11-02 GE GEAP201113106A patent/GEP201706733B/en unknown
- 2011-11-02 CN CN201710917166.3A patent/CN107522784B/zh active Active
- 2011-11-02 EP EP18188208.5A patent/EP3456740A1/en not_active Withdrawn
- 2011-11-02 EP EP17179739.2A patent/EP3281954A1/en not_active Withdrawn
- 2011-11-02 US US13/287,208 patent/US8778346B2/en active Active
- 2011-11-02 CA CA2816950A patent/CA2816950C/en active Active
- 2011-11-02 SI SI201130958A patent/SI2635601T1/sl unknown
- 2011-11-02 RS RS20160762A patent/RS55161B1/sr unknown
- 2011-11-02 MY MYPI2013001519A patent/MY162791A/en unknown
- 2011-11-02 PT PT117819490T patent/PT2635601T/pt unknown
- 2011-11-02 EP EP11781949.0A patent/EP2635601B1/en active Active
- 2011-11-02 ES ES11781949.0T patent/ES2593754T3/es active Active
- 2011-11-02 PL PL11781949T patent/PL2635601T3/pl unknown
- 2011-11-02 WO PCT/US2011/058869 patent/WO2012061448A1/en not_active Ceased
- 2011-11-02 HU HUE11781949A patent/HUE030916T2/en unknown
- 2011-11-02 HR HRP20161141TT patent/HRP20161141T1/hr unknown
- 2011-11-02 KR KR1020137011474A patent/KR101931591B1/ko active Active
- 2011-11-03 AR ARP110104094A patent/AR083747A1/es active IP Right Grant
- 2011-11-03 TW TW105114183A patent/TWI653242B/zh active
- 2011-11-03 TW TW100140204A patent/TWI545133B/zh active
- 2011-11-03 UY UY0001033703A patent/UY33703A/es active IP Right Grant
-
2012
- 2012-11-02 ME MEP-2016-176A patent/ME02499B/me unknown
-
2013
- 2013-04-09 IL IL225648A patent/IL225648A/en active Protection Beyond IP Right Term
- 2013-05-02 MA MA35866A patent/MA34641B1/fr unknown
- 2013-05-24 CO CO13128280A patent/CO6801628A2/es active IP Right Grant
- 2013-05-30 EC ECSP13012649 patent/ECSP13012649A/es unknown
-
2014
- 2014-06-12 US US14/302,986 patent/US9441036B2/en active Active
-
2016
- 2016-02-29 IL IL244335A patent/IL244335A/en active Protection Beyond IP Right Term
- 2016-08-04 US US15/228,254 patent/US10202448B2/en active Active
- 2016-09-13 CY CY20161100899T patent/CY1118014T1/el unknown
- 2016-12-16 AU AU2016273970A patent/AU2016273970B2/en active Active
-
2017
- 2017-01-13 JP JP2017003955A patent/JP6445596B2/ja active Active
-
2018
- 2018-09-24 AU AU2018236692A patent/AU2018236692C1/en active Active
- 2018-11-29 JP JP2018223469A patent/JP6758361B2/ja active Active
-
2019
- 2019-01-25 US US16/257,463 patent/US20190144534A1/en not_active Abandoned
- 2019-10-14 LU LU00132C patent/LUC00132I2/fr unknown
- 2019-10-14 HU HUS1900048 patent/HUS1900048I1/hu unknown
- 2019-10-15 LT LTPA2019518C patent/LTC2635601I2/lt unknown
- 2019-10-16 NL NL301013C patent/NL301013I2/nl unknown
- 2019-10-17 NO NO2019038C patent/NO2019038I1/no unknown
- 2019-10-17 CY CY2019040C patent/CY2019040I2/el unknown
-
2020
- 2020-10-09 US US17/066,994 patent/US20210198355A1/en not_active Abandoned
-
2024
- 2024-03-14 US US18/605,420 patent/US20250101093A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017079785A5 (enExample) | ||
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2017502695A5 (enExample) | ||
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2010526028A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| HRP20161141T1 (hr) | Anti-il-23 protutijela | |
| CN109311974A (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
| JP2020532965A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| JP2012501669A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2011514150A5 (enExample) | ||
| JP2013538553A5 (enExample) | ||
| JP2010534478A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| JP2012100667A5 (enExample) | ||
| JP2017512838A5 (enExample) | ||
| HRP20130204T1 (hr) | Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže | |
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| JP2016511277A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| JP2009519718A5 (enExample) | ||
| JP2016520595A5 (enExample) |